Activities per year
Abstract
Objectives. Nearly all cervical cancers are caused by high-risk human papillomavirus (HR-HPV). In Latvia, organized cytology-based cervical cancer screening is in opertation since 2009. In 2020 the agestandardized cervical cancer incidence in Latvia was 18. 4 cases per 100 000 (6th highest in Europe). No HR-HPV prevalence population-based studies have been conducted among Latvian women.
Materials and Methods. A cross-sectional study took place from February 2021 to February 2022. The data for HR-HPV testing were collected at the 10 GP practices (general population) and among women referred for colposcopy to the Riga East University Hospital colposcopy unit (colposcopy population).
Vaginal samples were collected with a self-sample device – a dry cotton swab (FLOQSwabsTM). Samples were analyzed with Cobas 4800 System for HPV 16 and 18 and pooled results of other HR-HPV types.
Results. The study included 1313 women, and 1274 participants provided a valid sample. The prevalence of any HR-HPV infection was 66.8% in the colposcopy population and 11.0% in the general population. In the colposcopy group (n = 530), HPV 16 was present in 34.2%, type 18 in 4.0%, and other HR-HPV types in 42.0%. In the general population group (n = 744), HPV 16 was present in 3. 5%, type 18 in 1.2%, and other high-risk types in 7.5%. The prevalence of any HR-HPV for colposcopy group was the highest for respondents up to 29 years of age (78%), and for 60–69 years (83%). The prevalence of any HR-HPV in general population was the highest in women aged 30–39 (17%), and 70+ (20%). Stratified regression model in the general population showed that HR-HPV follows a pattern of an STI–it was significantly associated with a higher number of lifetime sex partners, and marital status. It was also associated with less
recent gynecologist visit. HR-HPV in the colposcopy population was associated with a well-known factor for genital cancers – smoking.
Conclusions. We documented a high HR-HPV infection burden in Latvia. Any HR-HPV positivity was significantly associated with sexual and other health behavior, and healthcare-seeking factors.
Materials and Methods. A cross-sectional study took place from February 2021 to February 2022. The data for HR-HPV testing were collected at the 10 GP practices (general population) and among women referred for colposcopy to the Riga East University Hospital colposcopy unit (colposcopy population).
Vaginal samples were collected with a self-sample device – a dry cotton swab (FLOQSwabsTM). Samples were analyzed with Cobas 4800 System for HPV 16 and 18 and pooled results of other HR-HPV types.
Results. The study included 1313 women, and 1274 participants provided a valid sample. The prevalence of any HR-HPV infection was 66.8% in the colposcopy population and 11.0% in the general population. In the colposcopy group (n = 530), HPV 16 was present in 34.2%, type 18 in 4.0%, and other HR-HPV types in 42.0%. In the general population group (n = 744), HPV 16 was present in 3. 5%, type 18 in 1.2%, and other high-risk types in 7.5%. The prevalence of any HR-HPV for colposcopy group was the highest for respondents up to 29 years of age (78%), and for 60–69 years (83%). The prevalence of any HR-HPV in general population was the highest in women aged 30–39 (17%), and 70+ (20%). Stratified regression model in the general population showed that HR-HPV follows a pattern of an STI–it was significantly associated with a higher number of lifetime sex partners, and marital status. It was also associated with less
recent gynecologist visit. HR-HPV in the colposcopy population was associated with a well-known factor for genital cancers – smoking.
Conclusions. We documented a high HR-HPV infection burden in Latvia. Any HR-HPV positivity was significantly associated with sexual and other health behavior, and healthcare-seeking factors.
| Original language | English |
|---|---|
| Pages (from-to) | 63 |
| Journal | Medicina (Kaunas) |
| Volume | 59 |
| Issue number | Suppl.2 |
| Publication status | Published - Mar 2023 |
| Event | RSU Research Week 2023: Research Week 2023 Rīga Stradiņš University - Riga Stradins University, Riga, Latvia Duration: 27 Mar 2023 → 31 Mar 2023 https://rw2023.rsu.lv/general-information https://rw2023.rsu.lv |
Field of Science*
- 3.3 Health sciences
- 3.2 Clinical medicine
Publication Type*
- 3.4. Other publications in conference proceedings (including local)
Fingerprint
Dive into the research topics of 'Factors Associated with High-Risk Human Papillomavirus Infection in Population of Latvian Women'. Together they form a unique fingerprint.Activities
- 1 Oral presentation
-
Factors Associated with High-Risk Human Papillomavirus Infection in Population of Latvian Women
Bērza, N. (Speaker), Žodžika, J. (Co-author), Ķīvīte-Urtāne, A. (Co-author), Baltzer, N. (Co-author), Čurkste, A. (Co-author), Pole, I. (Co-author), Nygard, M. (Co-author), Parna, K. (Co-author), Stakunas, M. (Co-author) & Uuskula, A. (Co-author)
29 Mar 2023Activity: Talk or presentation types › Oral presentation